A Study of HS-20122 in Patients With Advanced Solid Tumors
ConditionAdvanced Solid Tumors
Trial statusRecruiting
Trial phasePhase 1
Trial typeInterventional
Biological sexAll
Age18+
SponsorHansoh BioMedical R&D Company
About this trial
This is a first-in-human (FIH) Phase I, multi-center, open-label, study of HS-20122, in patients with advanced solid tumors. This study will evaluate the safety, tolerability, pharmacokinetics and efficacy of HS-20122 in advanced solid tumors.
Eligibility criteria
Qualifiers
Males or females, aged ≥ 18 years.
Subjects with histologically or cytologically confirmed locally advanced or metastatic Solid Tumors
Standard treatment is invalid, unavailable or intolerable.
At least 1 target lesion according to RECIST 1.1.
Disqualifiers
Any unresolved toxicities from prior therapy greater than Grade 2 according to Common Terminology Criteria for Adverse Events (CTCAE) 5.0 with the exception of alopecia or neurotoxicity
History of other primary malignancies.
Inadequate bone marrow reserve or organ dysfunction.
Evidence of cardiovascular risk.
Trial design
Treatments tested in this trial
- HS-20122
Treatment groups
1,050 Participants
are divided into 1 treatment groupSponsors and collaborators
Source ClinicalTrials.gov